BCTXW BRIACELL THERAPEUTICS CORP C/WTS(TO PUR COM)
- 0.520
- +0.020+4.06%
BRIACELL THERAPEUTICS CORP C/WTS(TO PUR COM) News
Express News | Briacell Initiates Patient Enrollment in First-in-Human Study of Bria-Ots™ in Advanced Metastatic Breast Cancer
Express News | Briacell Announces Clinical Supply Agreement With Beigene for Bria-Ots™ First in Human Study
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
83% intracranial objective response rate (iORR) with Bria-IMT in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC resistant
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that
BriaCell Announces Oral and Poster Presentations at ASCO 2024
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell)
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+ and Bria-PROS+ Clinical Candidates for Breast and Prostate Cancer
Preclinical data shows that BriaCell's Bria-OTS+ and Bria-PROS+ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, a
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell's novel off-the-shelf personalized cancer va
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that
BriaCell Provides Update On Alleged Illegal Trading of Public Securities
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechno
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
Bria-Pros+ is based on BriaCell's next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells and natural
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnol
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient With "Eye-Bulging" Metastatic Breast Cancer
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT, alone and in combination with an immune checkpoint
BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset
In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell's combination regimen exceeded that of similar studies*Progression Free Survival (PFS) was similar or better
BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS
Median overall survival of 13.4 months in patients treated with the Bria-IMT combination regimen (vs. 6.7-9.8 months for similar patients reported in the literature*).32 out of 42 patients treated sin
BriaCell 2023 SABCS Posters Confirm Activation Of Cancer-Fighting Immune Cells And Identify Potential Predictors Of Clinical Benefit
BriaCell's Bria-IMT combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning "Cold" tumors "Hot" on ImmunoPET imaging.
BriaCell Records New Responder With Remarkable Improvement of "Eye-Bulging" Metastatic Tumor
After only 3 cycles, patient experienced a remarkable improvement of eye-bulging "proptosis" caused by orbital metastatic breast cancer tumor behind the eye. Significant ocular pain reduction recorded.Heavily treated
BriaCell Reports Unprecedented Anti-Tumor Activity of Its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS IND
BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell's next generation breast and prostate cancer immunotherapies Data supports further development of BriaCel
Analysis
Price Target
No Data
